Movement Alert｜Zai Lab Rises 5.57% in Regular Trading, Schizophrenia Drug Launch and Cervical Cancer Drug Approval Drive Dual Catalysts

Market Focus06-10

On June 10, Zai Lab rose 5.57% in regular trading, trading at HK$13.31/share, with trading volume of HK$178 million. The stock rallied on dual product milestones that boosted market sentiment.

On the news front, the company's first neuroscience product, xanomeline-trospium chloride capsules (KarXT), was officially shipped on June 9. The drug is now available in over 30 cities and nearly 50 hospitals nationwide, with the first prescription issued at Beijing Anding Hospital affiliated with Capital Medical University, targeting schizophrenia patients.

Additionally, China's National Medical Products Administration approved the marketing application for Tivdak (tisotumab vedotin for injection), indicated for adult patients with recurrent or metastatic cervical cancer who progressed during or after prior chemotherapy. The approval was based on statistically significant overall survival benefits demonstrated in the global Phase 3 innovaTV 301 clinical trial.

The simultaneous commercial launch of a neuroscience asset and regulatory approval of an oncology product represent meaningful pipeline catalysts, expanding Zai Lab's marketed portfolio and potential revenue base.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119493772?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 15:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119493772","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Zai Lab Rises 5.57% in Regular Trading, Schizophrenia Drug Launch and Cervical Cancer Drug Approval Drive Dual Catalysts","media":"Market Focus","content":"<p><p>On June 10, Zai Lab rose 5.57% in regular trading, trading at HK$13.31/share, with trading volume of HK$178 million. The stock rallied on dual product milestones that boosted market sentiment.</p><p>On the news front, the company's first neuroscience product, xanomeline-trospium chloride capsules (KarXT), was officially shipped on June 9. The drug is now available in over 30 cities and nearly 50 hospitals nationwide, with the first prescription issued at Beijing Anding Hospital affiliated with Capital Medical University, targeting schizophrenia patients.</p><p>Additionally, China's National Medical Products Administration approved the marketing application for Tivdak (tisotumab vedotin for injection), indicated for adult patients with recurrent or metastatic cervical cancer who progressed during or after prior chemotherapy. The approval was based on statistically significant overall survival benefits demonstrated in the global Phase 3 innovaTV 301 clinical trial.</p><p>The simultaneous commercial launch of a neuroscience asset and regulatory approval of an oncology product represent meaningful pipeline catalysts, expanding Zai Lab's marketed portfolio and potential revenue base.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Zai Lab Rises 5.57% in Regular Trading, Schizophrenia Drug Launch and Cervical Cancer Drug Approval Drive Dual Catalysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Zai Lab Rises 5.57% in Regular Trading, Schizophrenia Drug Launch and Cervical Cancer Drug Approval Drive Dual Catalysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-10 15:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 10, Zai Lab rose 5.57% in regular trading, trading at HK$13.31/share, with trading volume of HK$178 million. The stock rallied on dual product milestones that boosted market sentiment.</p><p>On the news front, the company's first neuroscience product, xanomeline-trospium chloride capsules (KarXT), was officially shipped on June 9. The drug is now available in over 30 cities and nearly 50 hospitals nationwide, with the first prescription issued at Beijing Anding Hospital affiliated with Capital Medical University, targeting schizophrenia patients.</p><p>Additionally, China's National Medical Products Administration approved the marketing application for Tivdak (tisotumab vedotin for injection), indicated for adult patients with recurrent or metastatic cervical cancer who progressed during or after prior chemotherapy. The approval was based on statistically significant overall survival benefits demonstrated in the global Phase 3 innovaTV 301 clinical trial.</p><p>The simultaneous commercial launch of a neuroscience asset and regulatory approval of an oncology product represent meaningful pipeline catalysts, expanding Zai Lab's marketed portfolio and potential revenue base.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"","article_id":"1119493772","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119493772","pubTimestamp":1781075384,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 10, Zai Lab rose 5.57% in regular trading, trading at HK$13.31/share, with trading volume of HK$178 million. The stock rallied on dual product milestones that boosted market sentiment.On the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09688":"再鼎医药"},"translate_title":"动静快讯|再鼎医药常规交易涨5.57%精神分裂症药物上市及宫颈癌药物获批驱动双重催化剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1},"content_text":"On June 10, Zai Lab rose 5.57% in regular trading, trading at HK$13.31/share, with trading volume of HK$178 million. The stock rallied on dual product milestones that boosted market sentiment.On the news front, the company's first neuroscience product, xanomeline-trospium chloride capsules (KarXT), was officially shipped on June 9. The drug is now available in over 30 cities and nearly 50 hospitals nationwide, with the first prescription issued at Beijing Anding Hospital affiliated with Capital Medical University, targeting schizophrenia patients.Additionally, China's National Medical Products Administration approved the marketing application for Tivdak (tisotumab vedotin for injection), indicated for adult patients with recurrent or metastatic cervical cancer who progressed during or after prior chemotherapy. The approval was based on statistically significant overall survival benefits demonstrated in the global Phase 3 innovaTV 301 clinical trial.The simultaneous commercial launch of a neuroscience asset and regulatory approval of an oncology product represent meaningful pipeline catalysts, expanding Zai Lab's marketed portfolio and potential revenue base.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119493772","isCrawlerRequest":true}